Disclosed is a pharmaceutical preparation wrapping LY294002. LY294002 is wrapped in a medicine and an auxiliary material, and the ratio of the weight of the medicine to that of the auxiliary material is: 1:1 to 1:20, so as to effectively control release of LY294002. A medicine for clinically treating a PI3K activity related disorder disease may be prepared, and particularly may be used for treating lymphocytic tumor and treating lymphocytic tumor metastasis.
